Schwarz Pharma's Middle Way
When the branded generics that long sustained Schwarz Pharma began losing value, and former Big Pharma partners took on their own distribution, the firm realized it must change. The mid-sized European company determined to aggressively in-license products and also began looking for companies to acquire. To fuel its aspirations, Schwarz made an unusual move for a family-owned European company; it issued public stock as a way to get cash and acquisition currency.
You may also be interested in...
Germany's Schwarz has invested heavily in its transition from a marketing organization into a development-based firm. Higher-than expected windfall revenues from generic omeprazole increase its chances of a successful transformation.
The notion of building up a new drug company with the unwanted, undersized products of ever-bigger Big Pharma is hardly new. But MedPointe, with its acquisition of Carter Wallace's medical products business, is aiming to build up a new firm faster and bigger than can be done simply by in-licensing.
Singulair’s Psychiatric AE Risks Still A Problem, But US FDA Has Limited Mitigation Options Remaining
Stakeholders suggested a ‘Dear Healthcare Provider’ letter or speaking about the risks to professional societies to emphasize the psychiatric adverse events that prompted a boxed warning for the now-generic asthma drug montelukast. The NY Attorney General is adding more pressure.